Wall Street Zen Upgrades Sabra Healthcare REIT (NASDAQ:SBRA) to "Hold"

Key Points

• Wall Street Zen upgraded Sabra Healthcare REIT (NASDAQ:SBRA) from "sell" to "hold"; overall analyst coverage is mixed but the MarketBeat consensus is a "Moderate Buy" with a $22 consensus target (1 Strong Buy, 4 Buy, 5 Hold).
• Sabra beat Q1 revenue and FFO estimates (revenue $221.8M, FFO $0.39 vs. $0.38 consensus), reported GAAP EPS of $0.16 in line with estimates, set FY2026 guidance at $1.55–$1.59 EPS, and declared a quarterly dividend of $0.30 (≈5.8% annualized yield).
• Near‑term risks include management saying it will revisit 2026 guidance after ~$400M of year‑to‑date investments and warnings that skilled‑nursing deal flow is tight with strong competition, which could pressure capital deployment and payout sustainability.

Sabra Healthcare REIT (NASDAQ:SBRA - Get Free Report) was upgraded by research analysts at Wall Street Zen from a "sell" rating to a "hold" rating in a note issued to investors on Saturday.

A number of other equities research analysts have also issued reports on the stock. UBS Group increased their target price on shares of Sabra Healthcare REIT from $20.00 to $21.00 and gave the stock a "neutral" rating in a report on Thursday, February 19th. Truist Financial increased their target price on shares of Sabra Healthcare REIT from $21.00 to $22.00 and gave the stock a "hold" rating in a report on Friday, March 13th. Citigroup increased their target price on shares of Sabra Healthcare REIT from $21.00 to $24.00 and gave the stock a "buy" rating in a report on Wednesday, February 18th. Weiss Ratings upgraded shares of Sabra Healthcare REIT from a "buy (b+)" rating to a "buy (a-)" rating in a report on Wednesday, March 18th. Finally, Scotiabank increased their target price on shares of Sabra Healthcare REIT from $20.00 to $21.00 and gave the stock a "sector perform" rating in a report on Monday, March 2nd. One equities research analyst has rated the stock with a Strong Buy rating, four have assigned a Buy rating and five have assigned a Hold rating to the company's stock. According to data from MarketBeat, Sabra Healthcare REIT currently has a consensus rating of "Moderate Buy" and a consensus target price of $22.00.

Sabra Healthcare REIT Price Performance

Sabra Healthcare REIT stock opened at $20.36 on Friday. The firm has a market cap of $5.13 billion, a PE ratio of 32.32, a price-to-earnings-growth ratio of 1.65 and a beta of 0.67. Sabra Healthcare REIT has a 52-week low of $17.04 and a 52-week high of $21.07. The company has a quick ratio of 4.29, a current ratio of 4.72 and a debt-to-equity ratio of 0.96. The company's 50 day moving average is $20.23 and its two-hundred day moving average is $19.33.

Sabra Healthcare REIT (NASDAQ:SBRA - Get Free Report) last released its earnings results on Wednesday, April 29th. The real estate investment trust reported $0.16 earnings per share (EPS) for the quarter, hitting analysts' consensus estimates of $0.16. The company had revenue of $221.75 million for the quarter, compared to analyst estimates of $209.20 million. Sabra Healthcare REIT had a net margin of 19.22% and a return on equity of 5.60%. The firm's quarterly revenue was up 20.9% on a year-over-year basis. During the same period in the prior year, the business earned $0.37 EPS. Sabra Healthcare REIT has set its FY 2026 guidance at 1.550-1.590 EPS. On average, research analysts expect that Sabra Healthcare REIT will post 1.5 EPS for the current fiscal year.

Institutional Investors Weigh In On Sabra Healthcare REIT

Hedge funds and other institutional investors have recently modified their holdings of the company. Focus Partners Wealth increased its stake in Sabra Healthcare REIT by 11.4% in the first quarter. Focus Partners Wealth now owns 23,146 shares of the real estate investment trust's stock valued at $404,000 after purchasing an additional 2,375 shares during the last quarter. EverSource Wealth Advisors LLC lifted its position in shares of Sabra Healthcare REIT by 150.7% during the 2nd quarter. EverSource Wealth Advisors LLC now owns 2,555 shares of the real estate investment trust's stock worth $47,000 after buying an additional 1,536 shares during the last quarter. First Trust Advisors LP lifted its position in shares of Sabra Healthcare REIT by 27.2% during the 2nd quarter. First Trust Advisors LP now owns 368,383 shares of the real estate investment trust's stock worth $6,793,000 after buying an additional 78,709 shares during the last quarter. Cerity Partners LLC lifted its position in shares of Sabra Healthcare REIT by 73.0% during the 2nd quarter. Cerity Partners LLC now owns 18,686 shares of the real estate investment trust's stock worth $345,000 after buying an additional 7,885 shares during the last quarter. Finally, Daiwa Securities Group Inc. lifted its position in shares of Sabra Healthcare REIT by 3.1% during the 2nd quarter. Daiwa Securities Group Inc. now owns 83,889 shares of the real estate investment trust's stock worth $1,547,000 after buying an additional 2,557 shares during the last quarter. 99.40% of the stock is currently owned by institutional investors and hedge funds.

Sabra Healthcare REIT News Summary

Here are the key news stories impacting Sabra Healthcare REIT this week:

• Positive Sentiment: Q1 top‑line and FFO beat — Sabra reported revenue of $221.8M (above estimates) and FFO of $0.39, beating consensus ($0.38), showing continued SHOP/senior‑housing contribution and improved cash flow dynamics. Sabra Healthcare (SBRA) Tops Q1 FFO and Revenue Estimates
• Positive Sentiment: FY‑2026 guidance nudged higher — company set EPS guidance of $1.55‑$1.59 vs. consensus ~1.50, implying modest upside to street earnings expectations. Press Release / Slide Deck
• Positive Sentiment: Dividend declared — quarterly dividend of $0.30/share (annualized yield ~5.8%), supporting income investor interest. (Company release)
• Positive Sentiment: Analyst support — at least one published note sets a $22 price target, indicating some analyst optimism on valuation upside. Analysts Set Sabra Healthcare REIT, Inc. NASDAQ: SBRA Price Target at $22.00
• Neutral Sentiment: SHOP/senior‑housing contribution highlighted — management and coverage note this was a driver of the quarter, an operational detail investors should watch for sustainability. Sabra Showcases Strong SHOP‑Driven Quarter
• Neutral Sentiment: Earnings metrics mixed — GAAP EPS of $0.16 met estimates but remains below last year’s quarter (affected by mix and non‑recurring items); slides and full call transcript are available for detail. Earnings Call Transcript / Presentation Q1 Presentation
• Negative Sentiment: Guidance subject to review — management said it will “revisit” 2026 guidance in Q2 after year‑to‑date investments of ~$400M, creating near‑term uncertainty about capital allocation and payout sustainability. Sabra Outlines Revisiting 2026 Guidance
• Negative Sentiment: Tighter deal flow and competition — CEO warned skilled‑nursing acquisition activity is tight and competition from private OpCo/PropCo buyers is fierce, which may limit attractive deployment opportunities and pressure future growth. CEO: Skilled Nursing Deal Flow Tight

Sabra Healthcare REIT Company Profile

Sabra Healthcare REIT, Inc NASDAQ: SBRA is a real estate investment trust that acquires, owns and operates net‐lease healthcare properties. Its diversified portfolio spans senior housing communities, skilled nursing and rehabilitation centers, outpatient medical facilities, medical office buildings, hospitals and life science properties. Sabra structures long‐term, triple‐net lease agreements with healthcare operators, providing stable rental income streams while allowing tenants to focus on patient care and operational excellence.

Serving a broad spectrum of care segments, Sabra's tenants include both regional and national providers of assisted living, independent living, memory care, post‐acute rehabilitation and research and development laboratories.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.